Memphis Co. for Pharmaceutical and Chemical Industries was founded in April 1940 during World War II in consequence to the appearance of huge shortage of medicine in Egypt as it was out sourced totally from the European countries at that time.
Starting from the beginning of this war till it ends, the company began to build its primary factory in Zeiton district and tried to equip it with the latest automatic machines and scientific devices in accordance to the latest automation in the pharmaceutical industry at that time.
To apply the new development pursued by Memphis Company, it was an urgent decision to expand horizontally and transfer the facilities with all the manufacturing sites to another industrial area as large as 16 acres area in Amirya district with the evolving of quality system guidelines in the field of pharmaceutical manufacturing.
The company has built the first sterile area in the Middle East for the production of sterile ampoules and ointments beside establishing a highly sophisticated facility for medicinal plant extracts that were exported to several countries in Asia, Europe, America and Canada, in addition to production of various pharmaceutical dosage forms such as tablets, capsules, syrups, ointments, creams , suppositories and veterinary products.
Memphis Co. now is an Egyptian joint venture company, 60% of the working capital is state-owned by Holding Company and the rest 40% is owned as public shares by a number of shareholders and part of it is owned by a labor union of the company.
The company owns three patency's certificates for its three unique extracts produced by the company (Amodin, amidine, Khellin) as well as three patent inventions for the treatment of patients with vitiligo, psoriasis and urinary tract complications.
The company's products and the facility daily systems are continuously subjected to complete quality control monitoring system to control all the steps of production and that includes the latest calibration schedule for all the devices and tools used during various operating stages. Memphis Company contributes to the national project scheduled by the Egyptian MOH for the treatment of liver diseases (virus C) by presenting "Pegferon" the main similar to the patent one long-acting interferon.
The company's products are mainly introduced from the Egyptian export market with a large number of unique products as well as Memphis got the right of manufacturing a large number of under-licensed pharmaceutical products owned by many international companies because of its famouslong and well-trained expertise and unique capabilities in the field of pharmaceutical Industry.
Dr/ Abla Yousef Abdel allah hassan Chairman of the Board & Managing Director
Dr/Alaa Eldeen Salah Khalil Non Executive Member
Mr/ Ahmed Ata Abdelaal Non Executive Member
Dr/ Maha Mohamed slim Non Executive Member
Mrs/ Omayma Ateya Abo Eleneen Acting as representative of the shareholders
Dr/ Sagy Anwar Abdel Shakoor Elected Member